SV2002000055A - Articulos de manufactura ref. n0. 29342/36212 sv - Google Patents

Articulos de manufactura ref. n0. 29342/36212 sv

Info

Publication number
SV2002000055A
SV2002000055A SV2000000055A SV2000000055A SV2002000055A SV 2002000055 A SV2002000055 A SV 2002000055A SV 2000000055 A SV2000000055 A SV 2000000055A SV 2000000055 A SV2000000055 A SV 2000000055A SV 2002000055 A SV2002000055 A SV 2002000055A
Authority
SV
El Salvador
Prior art keywords
manufacture
articles
pde5
ref
approximate
Prior art date
Application number
SV2000000055A
Other languages
English (en)
Inventor
Jeffrey Thomas Emmick
Jebbetg Nucgaek Ferguson
William Ernest Pullman
John Steven Witaker
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2002000055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of SV2002000055A publication Critical patent/SV2002000055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

EL PRESENTE INVENTO ESTA RELACIONADO CON INHIBIDORES ENZIMATICOS ALTAMENTE SELECTIVOS DE LA FOSFODIESTERASA (PDE) Y CON SU USO EN ARTICULOS FARMACEUTICOS DE MANUFACTURA. EN PARTICULAR, EL PRESENTE INVENTO SE RELACIONA CON POTENTES INHIBIDORES DE LA FOSFODIESTERASA ESPECIFICA DEL 3',5'-MONOFOSFATO DE GUANOSINA CICLICO TIPO 5(PDE5) LOS CUALES, INCORPORADOS A UN PRODUCTO FARMACEUTICO EN UNA DOSIFICACION UNITARIA DE APROXIMADAMENTE 1MG A APROXIMADAMENTE 20MG, SON UTILES PARA EL TRATAMIENTO DE LA DISFUNCION SEXUAL. LOS ARTICULOS DE MANUFACTURA AQUI DESCRITOS SON CARACTERIZADOS POR LA INHIBICION SELECTIVA DE LA PDE5 Y CORRESPONDIENTEMENTE, PROVEEN DE UN BENEFICIO EN AREAS TERAPEUTICAS DONDE ES DESEADA LA INHIBICION DE LA PDE5, CON MINIMIZACION O ELIMINACION DE EFECTOS COLATERALES ADVERSOS QUE RESULTEN DE LA INHIBICION DE OTRAS ENZIMAS FOSFODIESTERASAS.
SV2000000055A 1999-04-30 2000-04-25 Articulos de manufactura ref. n0. 29342/36212 sv SV2002000055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
SV2002000055A true SV2002000055A (es) 2002-07-03

Family

ID=22452153

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000055A SV2002000055A (es) 1999-04-30 2000-04-25 Articulos de manufactura ref. n0. 29342/36212 sv

Country Status (47)

Country Link
EP (2) EP1173181B3 (es)
JP (2) JP4975214B2 (es)
KR (2) KR20010020779A (es)
CN (2) CN1196487C (es)
AT (1) ATE251908T1 (es)
AU (3) AU3012900A (es)
BE (1) BE1012957A5 (es)
BR (2) BR0003046A (es)
CA (2) CA2371684C (es)
CH (2) CH1173181H1 (es)
CO (1) CO5170493A1 (es)
CZ (1) CZ296534B6 (es)
DE (3) DE60005940T3 (es)
DK (2) DK200000677A (es)
DZ (1) DZ3171A1 (es)
EA (2) EA200000355A3 (es)
ES (2) ES2187234A1 (es)
FI (1) FI20000976A (es)
FR (1) FR2795646B1 (es)
GB (1) GB2351663A (es)
GR (1) GR1003575B (es)
HK (1) HK1041204B (es)
HR (2) HRP20000243A2 (es)
HU (2) HUP0001632A3 (es)
ID (1) ID25704A (es)
IE (1) IE20000315A1 (es)
IL (3) IL135817A0 (es)
IT (1) ITMI20000922A1 (es)
LT (1) LT4758B (es)
LU (1) LU90569B1 (es)
LV (1) LV12560B (es)
MX (2) MXPA00003997A (es)
NL (1) NL1015027C2 (es)
NO (2) NO20002097L (es)
NZ (2) NZ514882A (es)
PE (1) PE20010071A1 (es)
PL (2) PL197813B1 (es)
PT (2) PT102457A (es)
SE (1) SE0001518L (es)
SG (1) SG98384A1 (es)
SI (2) SI20361A (es)
SK (1) SK285415B6 (es)
SV (1) SV2002000055A (es)
TR (1) TR200001132A3 (es)
UA (1) UA72248C2 (es)
WO (1) WO2000066099A2 (es)
ZA (2) ZA200002058B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72922C2 (uk) * 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
EP1289990A1 (en) * 2000-06-08 2003-03-12 Lilly Icos LLC Tetracyclic diketopierazine compounds as pdev inhibitors
EP1305313A1 (en) * 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
DE60219788T2 (de) 2001-06-05 2008-01-17 Lilly Icos Llc, Wilmington Tetrazyklische verbindungen als pde5-inhibitoren
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CA2647348A1 (en) 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR101663238B1 (ko) 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
WO2019154896A1 (de) * 2018-02-07 2019-08-15 Sapiotec Gmbh Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
EA199800907A1 (ru) 1996-05-10 1999-04-29 Айкос Корпорейшн Производные карболина
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
CA2339630C (en) 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US6613768B1 (en) * 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Also Published As

Publication number Publication date
CO5170493A1 (es) 2002-06-27
SI1173181T1 (en) 2004-04-30
AU4490800A (en) 2000-11-17
SI20361A (sl) 2001-04-30
BE1012957A5 (fr) 2001-06-05
SK15632001A3 (sk) 2002-02-05
NZ504163A (en) 2001-11-30
AU769946C (en) 2005-01-13
NO20015275L (no) 2001-12-06
DE60005940D1 (de) 2003-11-20
NZ514882A (en) 2003-08-29
PL339897A1 (en) 2000-11-06
LT2000035A (en) 2000-11-27
DK1173181T6 (en) 2015-04-27
BR0003046A (pt) 2002-07-23
KR20010020779A (ko) 2001-03-15
NO322013B1 (no) 2006-08-07
FI20000976A (fi) 2000-10-30
ZA200002058B (en) 2000-11-02
FR2795646B1 (fr) 2002-08-16
EP1173181B1 (en) 2003-10-15
IL135817A0 (en) 2001-05-20
DK200000677A (da) 2000-10-31
SE0001518L (sv) 2000-10-31
JP2000336043A (ja) 2000-12-05
ZA200108900B (en) 2003-03-26
DE60005940T2 (de) 2004-07-29
DE20007861U1 (de) 2000-08-24
BR0010181A (pt) 2003-02-25
PT102457A (pt) 2000-11-30
ITMI20000922A0 (it) 2000-04-26
EP1173181A2 (en) 2002-01-23
CA2371684A1 (en) 2000-11-09
PE20010071A1 (es) 2001-03-22
TR200001132A2 (tr) 2001-01-22
CA2371684C (en) 2007-10-23
EP1173181B3 (en) 2015-03-25
GR1003575B (el) 2001-05-14
WO2000066099A2 (en) 2000-11-09
HK1041204B (zh) 2004-03-05
CH1173181H1 (es) 2019-07-15
JP2002543116A (ja) 2002-12-17
LV12560A (en) 2000-11-20
TR200001132A3 (tr) 2001-01-22
HRP20000243A2 (en) 2001-12-31
IE20000315A1 (en) 2001-03-07
PL197813B1 (pl) 2008-04-30
LU90569B1 (fr) 2002-02-27
MXPA00003997A (es) 2002-03-08
NO20002097D0 (no) 2000-04-25
HUP0200912A2 (en) 2002-08-28
ES2187234A1 (es) 2003-05-16
CN1384746A (zh) 2002-12-11
NL1015027C2 (nl) 2001-02-14
HUP0001632A3 (en) 2001-12-28
SE0001518D0 (sv) 2000-04-26
EA200000355A2 (ru) 2000-10-30
DZ3171A1 (es) 2000-11-09
GB2351663A (en) 2001-01-10
ES2208317T3 (es) 2004-06-16
IL146098A0 (en) 2002-07-25
NO322013B3 (no) 2017-11-06
JP4975214B2 (ja) 2012-07-11
ID25704A (id) 2000-11-02
PL352629A1 (en) 2003-08-25
ES2208317T7 (es) 2015-09-15
AU769946B2 (en) 2004-02-12
CH692478A5 (de) 2002-07-15
EA005416B1 (ru) 2005-02-24
GB0010199D0 (en) 2000-06-14
DE10021266A1 (de) 2000-11-16
LV12560B (en) 2001-04-20
GR20000100153A (el) 2000-12-29
MXPA01010837A (es) 2002-11-07
KR100577057B1 (ko) 2006-05-10
FR2795646A1 (fr) 2001-01-05
NO20015275D0 (no) 2001-10-29
PT1173181E (pt) 2004-02-27
IL146098A (en) 2007-06-03
DE60005940T3 (de) 2015-08-27
HUP0001632A2 (hu) 2001-05-28
LT4758B (lt) 2001-02-26
CA2307101A1 (en) 2000-10-30
WO2000066099A3 (en) 2001-01-18
NO20002097L (no) 2001-10-26
EP1415652A2 (en) 2004-05-06
HU0001632D0 (en) 2000-06-28
ITMI20000922A1 (it) 2001-10-26
CA2307101C (en) 2003-01-28
SG98384A1 (en) 2003-09-19
HU230369B1 (hu) 2016-03-29
AU2004201988A1 (en) 2004-06-10
CZ296534B6 (cs) 2006-04-12
EP1415652A3 (en) 2004-05-12
DK1173181T3 (da) 2004-02-16
CZ20013879A3 (cs) 2002-04-17
CN1292264A (zh) 2001-04-25
KR20020008396A (ko) 2002-01-30
EA200000355A3 (ru) 2001-02-26
SK285415B6 (sk) 2007-01-04
FI20000976A0 (fi) 2000-04-26
HU0200912D0 (en) 2002-04-29
EA200101008A1 (ru) 2002-04-25
CN1196487C (zh) 2005-04-13
AU3012900A (en) 2000-11-02
HRP20010778B1 (en) 2005-04-30
HUP0200912A3 (en) 2003-07-28
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
NL1015027A1 (nl) 2000-10-31
ATE251908T1 (de) 2003-11-15
UA72248C2 (en) 2005-02-15

Similar Documents

Publication Publication Date Title
SV2002000055A (es) Articulos de manufactura ref. n0. 29342/36212 sv
CY1106239T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΔΙΑΜΟΡΦΩΣΕΙΣ ΕΛΕΓΧΟΜΕΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΗΣ ΠΟΥ ΠEPΙΕΧΟΥΝ ΑΝΑΣΤΟΛΕΑ cGMP PDE-5
CY1112949T1 (el) 2-φαινυλο-υποκατεστημενες ιμιδαζοτριαζινονες ως αναστολεις φωσφοδιεστερασης
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
CU23198A3 (es) COMPUESTOS FARMACéUTICAMENTE ACTIVOS
BR0109163A (pt) Uso de pirido[3,2-e]-pirazinonas como inibidores da fosfodieterase 5, para terapia de disfunção erétil
AR034059A1 (es) Producto que comprende mikanolido, dihidromikanolido o analogos de los mismos en combinacion con otro agente anticanceroso para uso terapeutico en el tratamiento del cancer
BR0110373A (pt) Inibidores da enzima fosfodiesterase (pde) e seu uso em artigos farmacêuticos industrializados
BR0115413A (pt) Tratamento de ejaculação precoce
ECSP034673A (es) Compuestos de azole como agentes anti-fungicos
ECSP024267A (es) Imidazotriazinonas sustituidas por 2-fenilo
AR024131A1 (es) 3,6-dihidro-pirazolo[3,4-d] [1,2,3] triazin-4-onas de efecto anticonvulsivo, procedimientos para su preparacion, su utilizacion para la preparacion demedicamentos y las composiciones farmaceuticas que los contienen
ECSP003429A (es) Productos de elaboracion
ECSP993165A (es) Formulaciones farmaceuticas de liberacion controlada
ECSP034842A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo[2,3-d] pirimidina
UY26753A1 (es) Derivados de 6-fenilpirrolpirimidina
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
FD Lapse